OBJECTIVES: Extracorporeal life support (ECLS) is a rescue option in critically ill patients. Since fast available and appropriate for respiratory and circulatory failure, it is frequently applied in resuscitation scenarios. Neurological injury is a complication common in ECLS patients limiting outcome, particularly after resuscitation. In this study, the institutional ECLS database was used to correlate neuron-specific enolase (NSE) serum peak values with outcome of patients supported with venoarterial (VA) ECLS during cardiopulmonary resuscitation (CPR).
BACKGROUND
Extracorporeal life support (ECLS) is an established therapy for respiratory and circulatory failure in critically ill patients. In experienced centres, it is speedily available and represents a rescue option that is frequently applied in severe shock and resuscitation scenarios. Nevertheless, mortality ranges from 5% in neonates to 70% after ECLS implantation during ongoing cardiopulmonary resuscitation (CPR) [1] . Major factors such as bleeding (10-30%) and thrombembolic complications as well as infections impact on the primary outcome in this patient population [2] . Also, neuronal injury, a common complication (up to 50%) in patients supported with extracorporeal devices, limits the outcome after ECLS [3] . Predicting the neurological outcome, particularly after CPR, is relevant to extending/maintaining an elaborate extracorporeal therapy. Therefore, early neurological assessment is essential for determining a therapeutic concept. This includes neuroimaging via computer tomography as well as functional tests with electroencephalography and somatosensory evoked potentials [4, 5] . Also, various scoring systems, such as the Apache III score, are used to predict survival and outcome of patients after CPR [6] . Finally, several biochemical serum markers such as neuronspecific enolase (NSE) and S100B proteins are used to predict neurological outcome. NSE has been proved to be a valid predictive and sensitive serum marker of neuronal injury [5] . Therefore, it may help to determine conclusive therapeutic concepts for patients with ECLS devices.
The association between NSE serum levels and patient outcome after ECLS treatment has not been investigated yet? We used the institutional Regensburg ECLS database to analyse NSE peak levels and outcome in patients supported with VA ECLS devices during CPR.
METHODS

Patient cohort
From January 2011 to August 2012, 31 patients were enrolled in this retrospective analysis of the prospectively obtained institutional ECLS database.
All adult patients (age >18 years) supported with a VA ECLS device applied in a resuscitation scenario were included. All patients required CPR prior to extracorporeal support. CPR was defined as severe hypotension refractory to norepinephrine/epinephrine infusion necessitating mechanical chest compression. Stabilization via VA ECLS was deemed necessary due to prolonged hypotension and failing restoration of normotensive circulation (estimated cardiac output <2.5 l/min and mean arterial blood pressure values <60 mmHg) under catecholamine support (more than epinephrine 4 μg/kg/min, norepinephrine 5 μg/kg/min). An additional group of 14 patients on ECLS was included in this study as reference cohort for NSE levels during ECLS. All patients of this control cohort were on extracorporeal support and had uneventful cerebral computer tomography (CT) scans without neuronal lesions and comorbidities, respectively. In accordance with the study cohort, NSE values were monitored within 12-24 h of ECLS initiation. Patient age was comparable in the study and the control cohort (55 ± 17 vs 52 ± 13 years, P = n.s.)
Extracorporeal circuit
Several systems were used for extracorporeal support (centrifugal pumps: Deltastream DP3, Medos, Inc., Stollberg, Germany; Rotaflow, Maquet Cardiopulmonary, Inc., Hirrlingen, Germany. Oxygenator: Cardiohelp IR, Quadrox PLS, Maquet Cardiopulmonary, Inc., Hirrlingen, Germany). Each system included a polymethylenpentene diffusion membrane oxygenator and a centrifugal/axial pump connected to a control panel with flow monitoring and bubble detection. The heparin-coated blood tubing circuit was primed with 600 ml electrolyte balanced solution. For venous outflow, percutaneous cannulae (21 Fr, 55 cm, Maquet, Inc., Hirrlingen, Germany) were used in 27 patients. Access via the right jugular vein was used in 2 patients due to failed insertion via the femoral vein. In 2 patients, venous outflow was achieved via right atrial cannulation (40 Fr, 32 cm, Jostra, Inc., Hirrlingen, Germany). For arterial inflow femoral (29 patients; 15 Fr, 15 cm, Maquet, Inc., Hirrlingen, Germany) or ascending aortic access (2 patients; 15 Fr, 15 cm, Maquet, Inc., Hirrlingen, Germany) was obtained. If reasonable, anticoagulation was driven with intravenous heparin infusion with an ACT target range of 120-150 s.
After establishing the ECLS circuit with an initial blood flow rate up to 4.0 l/min, vasopressor support was titrated to maintain a mean arterial blood pressure of 50-60 mmHg. Initial pressurecontrolled ventilation with FiO 2 of 1.0 during CPR was reduced to lung protective setting. Following CPR, mild hypothermia (33-34°C) was applied for neuroprotection over 24 h.
Analgesic sedation during extracorporeal support was performed with continuous infusion of propofol or midazolam/sufentanil in case of high-dosage vasopressor support due to severe circulatory depression.
Weaning criteria from extracorporeal circuit were stabilized circulatory status with serum lactate <20 mg/dl, sufficient cardiac function (assessed by echocardiography), mean arterial blood pressure >70 mmHg with low catecholamine support and mixed venous oxygen saturation >65% during an extracorporeal blood flow of 1.0-1.5 l/min for at least 6 h.
Criteria for terminating conservative and extracorporeal therapy were failing stabilization of patients with prolonged mean blood pressure levels <50 mmHg and increasing serum lactate despite high-dosage vasopressor support (epinephrine, norepinephrine and vasopressin) and maximum extracorporeal pump flow up to 5.0 l/min. Furthermore, additional criteria for limiting therapeutical efforts were severe neuronal lesions, such as fulminant cerebral infarction or manifest cerebral herniation confirmed via cerebral CT imaging.
Levels of serum lactate, pH and catecholamine support were recorded prospectively prior to ECLS implantation, and 4 h and 24 h after implantation.
Neuroimaging and NSE monitoring
NSE levels were monitored within 12-24 h of ECLS implantation. Quantitative analysis of whole blood serum samples was performed using an electroluminiscence immunoassay (Roche Diagnostics Ltd, Mannheim, Germany). NSE levels were repeatedly monitored within 48 h of ECLS implantation, and for this analysis, only values monitored within a 24 h time frame were used.
Prior to resuscitation, no patient had evidence for comorbidities associated with increased NSE synthesis.
Cerebral CT scans were performed with a 16-slice CT canner (Siemens Somatom Sensation 16, Siemens Healthcare AG, Erlangen, Germany) with a 4-8 mm slice thickness for reconstruction.
For analysis, patients were arbitrarily assigned into two groups with mild-to-moderate and high NSE serum levels and a NSE cut-off level of 100 μg/l.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 5.03 (GraphPad, Inc., San Diego, CA, USA). Differences of continuous variables were calculated by the Mann-Whitney test and are given as mean values with standard deviation. For calculation of sensitivity, specitivity, and predictive value, Fisher's exact test was used. To test diagnostic accuracy, receiver-operating curve analysis with cerebral CT imaging as reference was performed. P-values <0.05 were considered statistically significant.
RESULTS
All 31 patients received VA ECLS device during ongoing CPR augmented with high inotropic and vasopressor catecholamine infusion. Baseline characteristics and pathology leading to circulatory collapse and subsequent CPR are given in Table 1 . Time of resuscitation prior to ECLS in all patients was 48 ± 32 min. Intervals of CPR were comparable in patients with moderate and high NSE values (46 ± 34 vs 54 ± 26 min, P = n.s.). Also, patients with and those without neurological injury showed comparable times of resuscitation (44 ± 31 vs 51 ± 33 min, P = n.s.). Peripheral vascular disease was evident in 5 patients (9%), and of 10 patients with ultrasound imaging of supra-aortic vessels, only 1 patient presented with a relevant stenosis of carotid arteries.
Following ECLS implantation, serum NSE levels exceeded the 100 μg/l cut-off value (mean 218 ± 155 μg/l, range 108-536 μg/l) in 7 patients. Twenty-four patients had mild-to-moderate NSE peaks <100 μg/l (mean 50 ± 23 μg/l, range 15-97 μg/l, P = 0.0001) (Fig. 1) .
Correspondingly, mean NSE values of the reference ECLS cohort (49 ± 23 μg/l, range 15-93 μg/l) without neuronal injury were comparable with those of the mild-to-moderate group (P = n.s.) and significantly lower than those of the high-NSE group with 6 patients displaying severe neuronal injury (P = 0.0003).
In the study cohort, 22 patients (71%) underwent neuroimaging via cerebral CT, and in 9 patients imaging was not performed due to severe haemodynamic instability despite extracorporeal support (5 patients) or good neurological outcome within 48 h of CPR (4 patients).
The duration of ECLS was comparable in both groups (6.3 ± 7.5 vs 5.0 ± 4.5 days, P = n.s.).
Overall, from the entire 31-patient cohort, 22 patients could be weaned from extracorporeal support after a median of 5.6 ± 5.8 days. Ratios of successfully weaned patients were comparable in both groups (mild-to-moderate vs high NSE: 11 (75%) vs 4 (57%) patients (P = n.s.). Analysis of in-hospital mortality (overall: 55%) revealed a trend of better outcome in patients with mild-to-moderate NSE peaks in contrast to patients with high values, without achieving statistical significance (mild-to-moderate vs high NSE: 11 (46%) vs 6 (86%) patients, P = 0.09).
Twelve patients (38%) suffered ischaemic and/or haemorrhagic stroke. Neurological outcome was inferior in the high-NSE group compared with the mild-to-moderate peak group, with cerebral lesions being significantly increased (mild-to-moderate vs high NSE: 6 (29%) vs 6 (86%), P = 0.007). In this particular group of patients with stroke, all patients with NSE values >100 μg/l featured severe neurological adverse events, such as multiple strokes or cerebral oedema causing herniation. In contrast, only 1 patient ( peak 96 μg/l) of the mild-to-moderate NSE group experienced severe neuronal injury with multiple lesions (cerebellum, brain stem, peripheral temporal lobe and basal ganglia).
Of note, patients with mild-to-moderate NSE peak were significantly older than their counterparts with high NSE peaks (58 ± 16 vs 44 ± 15 years, P = 0.02). Prior to extracorporeal support, mean serum lactate was significantly higher in the high-NSE group (106 ± 11 vs 161 ± 16 mg/l, P = 0.023). Also, mean serum-pH before support was lower in patients with higher NSE values later on (6.93 ± 0.12 vs 7.23 ± 0.04, P = 0.039) ( Table 2) .
Based on these data, sensitivity, specificity and the positive predictive value of NSE peaks were calculated. In-hospital mortality: 0.64, 0.07 and 0.45; neurological event: 0.94, 0.5 and 0.75 and severe neurological event (defined as multiple lesions or cerebral oedema causing herniation): 1.0, 0.85 and 0.83, respectively.
In 22 patients, CT imaging receiver-operating curve analysis comparing diagnostic accuracy of NSE peaks, serum lactate and serum pH values prior to extracorporeal support revealed an area under the curve (AUC) of 0.79 (P = 0.023) for NSE levels. In Myocardial infarction n = 9 Pulmonary embolism n = 6 Acute coronary syndrome n = 3 Pericardial tamponade n = 4 Ventricular fibrillation n = 4 Low cardiac output n = 3 Other (sepsis, dilatative cardiomyopathy) n = 2 Previous cardiac surgery n = 9 contrast, AUC values for lactate and pH were 0.54 (P = n.s.) and 0.71 (P = n.s.), respectively (Fig. 2) .
DISCUSSION
Extracorporeal support covers severe respiratory as well as circulatory failure and offers survival rates up to >50% in a severely ill patient population, depending on underlying pathology, setting of extracorporeal circuit and concomitant organ function [7] [8] [9] [10] .
Especially in patients with sepsis and with ECLS applied in resuscitation scenarios, outcome is still poor [11, 12] . Nevertheless, since ECLS is a rescue option, it is frequently applied during ongoing CPR to restore sufficient perfusion as fast as possible without identifying all particular case aspects before. In the face of poor neurological outcomes in up to 80% after cardiac arrest and resuscitation, speedily available ECLS is reasonable and should be applied liberally along with a 'time is brain' rule. In order to address the issue of neuronal injury, a routinely monitored and reliable prognostic marker is reasonable to develop therapeutic concepts following CPR, taking into account the limitation of elaborate extracorporeal therapy, if appropriate. In this study, NSE peaks in patients supported with ECLS during CPR were analysed regarding survival and neurological outcome. NSE values were monitored within a 12-24 h time frame after begin of ECLS support. Since the serum half-life of serum NSE is up to 24 h, a bias affecting results may be negligible.
Overall mortality was comparable with literature data on ECLS therapy in this selected patient population [8, 9, 11] . In contrast to comparable support intervals and weaning rates, patients with extensive NSE elevation featured not only a higher rate of neuronal injury, but also higher severity of neuronal lesions compared with individuals with mild or moderate NSE elevation.
NSE is widely used for assessing prognosis after cardiac arrest/ CPR. Based on a prospective analysis with 407 patients included in normothermic patients, NSE values >33 ng/ml are highly predictive for poor outcome [13] . Along with this, cut-off values of 30-80 ng/ml have been associated with poor neurological outcome, i.e. persistent coma, in patients after cardiac arrest/CPR without extracorporeal support [14] . In contrast, analyses of patients provided with neuroprotective hypothermia after CPR revealed higher threshold values comparable with the cut-off used in this study [15, 16] . Of note, in the patient cohort analysed, 4 patients featured NSE peaks of 65-100 ng/ml with excellent neurological outcome in 3 of 4 cases. This evident threshold discrepancy is explained not only by neuroprotective hypothermia applied in all the included patients after CPR, but also by red blood cells containing NSE, leading to a serum increase in case of haemolysis which is a given side effect of extracorporeal circuits [17, 18] . Therefore, to exclude high NSE levels as a device-related effect, patients on ECLS without neuronal injury confirmed by CT imaging were included as reference cohort in this analysis. Since NSE height in this cohort was comparable with that in the mild-to-moderate group, initial NSE peaks >100 μg/l caused solely by extracorporeal circuit triggered haemolysis are unlikely.
In contrast to neurological outcome, there was merely a trend evident to reduced in-hospital mortality in patients with only moderately increased NSE. This may be caused by the small number of patients exceeding the NSE 100 μg/ml cut-off, and may reach clearer evidence with more patients included.
Correspondingly, sensitivity and predictive value of NSE for hospital mortality were not sufficient to draw any relevant implications for maintaining or limiting elaborate extracorporeal therapy. Along with other studies adverse neurological outcome could be reliably predicted. Therefore, our institution favours NSE as a speedily available and case-sensitive supplemental tool to detect early neuronal injury. To improve sensitivity and specitivity and predictive value in this patient setting, monitoring of additional markers (i.e. S100 protein) or combination with functional neuronal testing (i.e. somatosensory evoked potentials) is reasonable, as increased predictability of neurological outcome by use of two diagnostic tools after cardiac arrest has been shown previously Receiver-operating curve analysis/area under curve calculation to test the diagnostic accuracy of NSE, time of CPR, lactate and pH values prior to ECLS. Cerebral CT imaging was used as reference; 22 patients were included. [19] . Routine implementation of a two-stage neuronal diagnostic monitoring after ECLS in resuscitation may also be favourable to prevent recently reported hypothermia affecting prognostic values of NSE and S100 after cardiac arrest-in contrast to unaffected SSEP monitoring [20] . In this study, NSE levels were analysed retrospectively. Due to this evidence, prospective institutional treatment protocols implement extended neuronal monitoring with another marker, S100 protein, or additional SSEP monitoring in patients with ECLS after resuscitation. However, this method is not aimed to replace profound cerebral diagnostic assessment, but it may help to initiate diagnostic efforts at an early stage and to determine a therapeutic path right in time.
Unexpectedly, patients with high NSE peaks were significantly younger than their counterparts with mild-to-moderate peaks. Hence, age does not seem to be a primary variable with regard to outcome after CPR. In contrast, serum pH-and lactate values prior to ECLS implantation reflected insufficient prolonged perfusion and corresponded to the neurological outcome in our patient cohort. Serum lactate is widely used as monitoring marker to assess patients' haemodynamic status and for risk stratification [21] . Despite a reported correlation between lactate levels and mortality/morbidity, there is no valid predictive value of lactate and serum-pH based on controlled trials [22] . However, in a 73-patient cohort with cardiogenic shock rescued with ECLS, lactate levels and subsequent decrease have been identified as predictors for mortality [23] .
Finally, there are some limitations of this study: first, the variable time/duration of CPR, potentially relevant to outcome, has not been considered in this analysis. Reported data regarding this issue are conflicting. In a prospective analysis, prolonged resuscitation has been associated with decreased survival after cardiac arrest and CPR, and use of extracorporeal support has been shown to increase survival significantly [24] . In contrast, a recent work including >60 000 patients with cardiac arrest did not find evidence for time of CPR correlating with any kind of outcome. Neurological outcome was not affected by duration of CPR too [25] . Institutional experience has revealed a relevant impact of CPR duration on weaning and survival with better outcome of patients resuscitated <30 min and provided with ECLS after cardiac arrest [11] .
However, in this study, the variable time was not shown to affect outcome with comparable duration of CPR in both groups. In a tertiary care hospital with intensive care/emergency room staff who are well trained in resuscitation algorithms, time of CPR should be an issue of minor relevance for patients with in-hospital cardiac arrest. Also, the cut-off value for this retrospective study was chosen arbitrarily, based on evidence reported before in patients treated with hypothermia after CPR, since hypothermia is an implemental component of the treatment algorithm after CPR in our institution [15, 16] . For further evaluation, a primary prospective investigation with larger patient cohorts is mandatory.
CONCLUSION
Despite immediate haemodynamic stabilization, ECLS in CPR is associated with high mortality. Neurological injury is common, but is reliably predicted by high NSE-serum levels following ECLS implantation. In regard to mortality predictive value of NSE is limited. In case of increased NSE peak levels after ECLS, cerebral imaging is reasonable for determining a therapeutic strategy at an early stage.
